Osteocalcin Promoter-Mediated Expression of Therapeutic Genes in Localized and Metastatic Human Prostate Cancer
Abstract
Osteocalcin (OC) expresses in both normal and cancerous prostate epithelial cells and prostate cancer metastasis to the bone and lymph node. The goal of this research is to develop a novel therapeutic agent(s) based on osteocalcin promoter for the treatment of prostate cancer, particularly bone metastasis. Three therapeutic agents were proposed for testing: thymidine kinase (TK), cytosine deaminase (CD), and Diphtheria toxin interleukin 13 fusion toxin (DT-IL13). Recombinant adenovirus, Ad-OC-TK, carrying TK under the control of mouse OC promoter, with prodrug, has therapeutic efficacy on hormone refractory prostate cancers in animal models and had no toxic side effects in our formal toxicology study.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2002
- Accession Number
- ADA413350
Entities
People
- Chinghai Kao
Organizations
- Indiana University